- IPR policy: Noble intent but challenges galore
- Who Gains from the Modi Government’s Intellectual Property Rights Policy?
- Why New IPR Policy Is Inadequate
- TB patients protest outside health ministry, promised proper drug regimes from July
- Leaked letters show trade tensions over Colombian CL for Novartis’ Gleevec
Category Archives: Indian Patent Law
Economic Times, November 28, 2015. Mumbai – A division bench of the Delhi High Court sided with Roche against Indian firm Cipla, upholding the Swiss drug maker’s patent claims on key lung cancer drug erlotinib hydrochloride, branded Tarceva. The ruling is … Continue reading
Nature reviews. By Bhaven N. Sampat and Kenneth C. Shadlen. Patent protection for drugs in India has been a contentious issue in recent years, with several high-profile denials of patents — for example, for Novartis’ anticancer drug imatinib mesylate (Glivec; also … Continue reading
The IPR Think Tank was convened in November 2014 by Department of Industrial Policy & Promotion (DIPP), Ministry of Commerce, Government of India, to draft a national IPR Policy for India. Medécins Sans Frontières gives its views on the final version … Continue reading
NEW DELHI: In a reaction to the leak of the final draft of India’s new IPR policy on this blog and comments from spicy-ip, Commerce and Industry Minister Nirmala Sitharaman stated last Thursday that the leaked draft policy is not the final version , … Continue reading
Final draft, India National IPR Policy, by IP Think Tank constituted by DIPP, Ministry of Commerce and Industry
Comment by Knowledge Ecology International on India’s leaked IPR policy draft posted on this blog. October 14, 2015
Source: Daily Nation; October 6, 2015 Kenya may be forced to increase its future annual health budget, if global drug companies have their way in the simmering patents row surrounding the manufacture of medicines. They have pushed India, Kenya’s biggest … Continue reading
Source: Reuters 7 Sep 2015 India has again denied Pfizer Inc a patent on its rheumatoid arthritis drug tofacitinib, the latest setback for a multinational drugmaker seeking to enforce its intellectual property rights in the country.